Future cardiologyPub Date : 2024-04-25Epub Date: 2024-06-28DOI: 10.1080/14796678.2024.2356995
Jaouad Azzahhafi, Dean Rpp Chan Pin Yin, Mirjam Epping, Hajar Bofarid, Sem Aof Rikken, Thijs Verhagen, Rene Boomars, Anja Radstok, Jaco Houtgraaf, Angela Bikker, Jurriën M Ten Berg
{"title":"Pre-hospital evaluation of chest pain patients using the modified HEART-score: rationale and design.","authors":"Jaouad Azzahhafi, Dean Rpp Chan Pin Yin, Mirjam Epping, Hajar Bofarid, Sem Aof Rikken, Thijs Verhagen, Rene Boomars, Anja Radstok, Jaco Houtgraaf, Angela Bikker, Jurriën M Ten Berg","doi":"10.1080/14796678.2024.2356995","DOIUrl":"10.1080/14796678.2024.2356995","url":null,"abstract":"<p><p><b>Background:</b> This study assesses how ambulance paramedics using the modified HEART-score with a point-of-care cardiac troponin (cTn) compare to the emergency physicians using the modified HEART-score with a high-sensitive cTn (hs-cTn) in patients with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS), focusing on interobserver agreement and diagnostic performance. <b>Methods:</b> In this prospective multicenter cohort, we compare four cTn testing strategies (serial point of care and hs-cTn cTn measurement) with and without the HEART-score. Outcomes include the HEART-score's interobserver agreement, NSTE-ACS at discharge, major adverse cardiovascular events (MACE) after 30 days, and diagnostic accuracy of the different strategies. <b>Conclusion:</b> The POPular HEART study aims to improve NSTE-ACS diagnostic pathways, promoting pre-hospital detection and ruling out of NSTE-ACS to minimize unnecessary hospitalizations and associated costs.<b>Clinical Trial Registration:</b> NCT04851418 (ClinicalTrials.gov).</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"241-250"},"PeriodicalIF":1.6,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-04-25Epub Date: 2024-06-20DOI: 10.1080/14796678.2024.2360845
Laura Piscitelli, Antonio Gianluca Robles, Roberto Costantino, Valentina Forte, Silvio Romano, Luigi Sciarra, Francesco Bartolomucci, Domenico Riccardo Rosario Chieppa
{"title":"STEMI or not STEMI? A multimodality imaging approach to a challenging intracardiac mass with a tricky presentation.","authors":"Laura Piscitelli, Antonio Gianluca Robles, Roberto Costantino, Valentina Forte, Silvio Romano, Luigi Sciarra, Francesco Bartolomucci, Domenico Riccardo Rosario Chieppa","doi":"10.1080/14796678.2024.2360845","DOIUrl":"10.1080/14796678.2024.2360845","url":null,"abstract":"<p><p>Cardiac tumors, due to the various clinical scenarios and their histological subtypes, are still challenging for clinicians. They are differentiated into primary and secondary. The latest are more common and are usually lung and breast cancers, melanomas, and lymphoma metastasis. We present a case of a 73-year-old woman, with a history of breast cancer 10 years earlier, admitted to Cath lab for an elevation of the ST-segment of the electrocardiogram, myocardial infarction. Echocardiogram showed a curious abnormality in the myocardial wall. Thanks to a multimodality imaging strategy, including contrast-enhanced echocardiography and cardiac magnetic resonance, characterization of the underlying pathology was clear and, thus, the appropriate management and therapy.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"263-268"},"PeriodicalIF":1.6,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-04-25Epub Date: 2024-05-28DOI: 10.1080/14796678.2024.2354623
Abeline R Watkins, Ryaan El-Andari, Andy Liu, Blaine Achen, Jayan Nagendran
{"title":"Anomalous coronary artery masquerading as a root abscess: a case report.","authors":"Abeline R Watkins, Ryaan El-Andari, Andy Liu, Blaine Achen, Jayan Nagendran","doi":"10.1080/14796678.2024.2354623","DOIUrl":"10.1080/14796678.2024.2354623","url":null,"abstract":"<p><p>Congenital coronary artery anomalies are rare and most often clinically benign. We present a case of a 67-year-old male with osteomyelitis and persistent bacteremia with an anomalous left coronary artery mimicking an aortic root abscess. A transesophageal echocardiogram revealed a hypoechoic potential space around the aortic root, highly suspicious for a root abscess. Urgent cardiac surgery was performed, revealing no infection but an anomalous coronary artery arising from the right coronary sinus. This case highlights the importance of considering atypical anatomy in the diagnosis of infectious cardiac processes. While this resemblance should not delay intervention for suspected abscesses, it emphasizes the need to be aware of congenital differences in imaging for patients with known anomalies or asymptomatic patients with unknown anatomy.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":"20 5-6","pages":"275-280"},"PeriodicalIF":1.6,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-03-11Epub Date: 2024-05-03DOI: 10.1080/14796678.2024.2345002
Ioannis Skalidis, Dimitri Arangalage, Ioannis Kachrimanidis, Panagiotis Antiochos, Konstantinos Tsioufis, Stephane Fournier, Emmanouil Skalidis, Iacopo Olivotto, Niccolo Maurizi
{"title":"Metaverse-based cardiac magnetic resonance imaging simulation application for overcoming claustrophobia: a preliminary feasibility trial.","authors":"Ioannis Skalidis, Dimitri Arangalage, Ioannis Kachrimanidis, Panagiotis Antiochos, Konstantinos Tsioufis, Stephane Fournier, Emmanouil Skalidis, Iacopo Olivotto, Niccolo Maurizi","doi":"10.1080/14796678.2024.2345002","DOIUrl":"10.1080/14796678.2024.2345002","url":null,"abstract":"<p><p><b>Introduction:</b> Cardiac magnetic resonance imaging (CMR) is vital, but claustrophobia affects 10% of patients. The metaverse, an immersive virtual and augmented reality environment, has healthcare potential. We present a metaverse-based CMR simulation for claustrophobic patients. <b>Methods:</b> Three cardiomyopathy patients, initially CMR-refusing due to claustrophobia, received training via a virtual reality headset in a metaverse-based virtual hospital. Training efficacy was assessed through questionnaires and anxiety scales. <b>Results:</b> The patients successfully completed metaverse-based training, adapting to the CMR simulation. On CMR day, all entered the machine without issues and with reduced anxiety. Patients found the training useful, suggesting platform familiarization. <b>Discussion:</b> Our study demonstrates the metaverse's potential in alleviating CMR-related claustrophobia. The immersive nature enhances patient preparation, although usability improvements are needed. Further research should compare this approach with alternatives.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"191-195"},"PeriodicalIF":1.6,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-03-11Epub Date: 2024-07-04DOI: 10.1080/14796678.2024.2373558
Marco Maria Dicorato, Pierpaolo Caretto, Caterina Colucci, Michele Ciaccia, Marco Rella, Eluisa Muscogiuri, Paolo Colonna
{"title":"Cardiac magnetic resonance in a rare case of recurrent mesalazine-induced myocarditis.","authors":"Marco Maria Dicorato, Pierpaolo Caretto, Caterina Colucci, Michele Ciaccia, Marco Rella, Eluisa Muscogiuri, Paolo Colonna","doi":"10.1080/14796678.2024.2373558","DOIUrl":"10.1080/14796678.2024.2373558","url":null,"abstract":"<p><p>Mesalazine represents a key treatment for intestinal bowel diseases and only in rare cases produces cardiac toxicity, with a not completely known mechanism. We report a case of a 25-year-old man with a first episode of myocarditis after 2 weeks from the first mesalazine intake, documented also by a characteristic cardiac magnetic resonance pattern. Then, after less than 1 month, he suffered myocarditis recurrence and so, guided by a multidisciplinary team evaluation, in the suspicion of mesalazine-induced myocarditis, the drug was promptly stopped, with consequent recovery of cardiac damage. In our patient, the recurrence of myocarditis because of the non-interruption of the drug is very peculiar (only three cases described in literature) and definitively confirms the diagnosis.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"183-189"},"PeriodicalIF":1.6,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-03-11Epub Date: 2024-05-31DOI: 10.1080/14796678.2024.2354079
Michael Griffin, Gregory Yh Lip
{"title":"Clinical trial evaluation: the EDOSURE clinical trial program.","authors":"Michael Griffin, Gregory Yh Lip","doi":"10.1080/14796678.2024.2354079","DOIUrl":"10.1080/14796678.2024.2354079","url":null,"abstract":"<p><p>EDOSURE is a trial program of the direct oral anticoagulant drug edoxaban, comprising ten randomized clinical trials of which eight are currently published. They evaluate the use of edoxaban in the treatment of nonvalvular atrial fibrillation and acute venous thromboembolism, including in special circumstances such as patients undergoing cardiac procedures, cancer-associated venous thromboembolism, and elderly patients whose bleeding risk precludes conventional anticoagulation strategies. As a result of the collective evidence generated by EDOSURE, edoxaban is now recommended as a treatment option by numerous international guidelines. This review summarizes the context, rationale, and key findings of the studies.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":"20 4","pages":"171-177"},"PeriodicalIF":1.6,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-02-01Epub Date: 2024-01-26DOI: 10.2217/fca-2023-0103
Avichal Dani, Pari Shah, Dev Desai
{"title":"Noninvasive imaging modalities in coronary artery disease: a meta analysis comparing coronary computed tomography angiography and standard of care.","authors":"Avichal Dani, Pari Shah, Dev Desai","doi":"10.2217/fca-2023-0103","DOIUrl":"10.2217/fca-2023-0103","url":null,"abstract":"<p><p><b>Introduction:</b> Coronary artery disease has become a global pandemic and a major cause of death. The risk-factor calculation for coronary artery damage is an invasive procedure. <b>Aim:</b> To compare coronary computed tomography angiography (CCTA) with standard of care (SOC) to calculate need for revascularization, invasive coronary angiography as well as for myocardial infarction (MI) incidence and all-cause mortality. <b>Methodology, results & conclusion:</b> CCTA is significantly correlated with a reduction in MI episodes (RR = 0.752, 95% CI = 0.578-1.409; p < 0.033) and an increase in revascularizations (RR = 1.401, 95% CI = 1.315-1.492; p < 0.001) and invasive coronary angiography procedures (RR = 1.304, 95% CI = 1.208-1.409; p < 0.001). However, it was found that it did not affect all-cause mortality. On the contrary, standard care approaches were associated with greater rates of MI but lesser referrals for invasive coronary angiography and revascularization.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"81-88"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-02-01Epub Date: 2024-03-26DOI: 10.2217/fca-2023-0123
Charlie Lin, Andrew Nguyen, Ian Ling, Rod Partow-Navid, Steven Leung, Andrew Zadeh, Ivan Ho, Junaid Ab Zaman
{"title":"SuperMap algorithm: an efficient, safe and accurate modality for mapping and eliminating challenging cardiac arrhythmias.","authors":"Charlie Lin, Andrew Nguyen, Ian Ling, Rod Partow-Navid, Steven Leung, Andrew Zadeh, Ivan Ho, Junaid Ab Zaman","doi":"10.2217/fca-2023-0123","DOIUrl":"10.2217/fca-2023-0123","url":null,"abstract":"<p><p>Even with the development of advanced catheter-based mapping systems, there remain several challenges in the electrophysiological evaluation and elimination of atrial arrhythmias. For instance, atrial tachycardias with irregular rates cannot be reliably mapped by systems that require stability in order to sequentially gather data points to be organized thereafter. Separately, these arrhythmias often arise following initial ablation for atrial fibrillation, posing logistic challenges. Here, we present the available literature summarizing the use of a non-contact mapping catheter, the AcQMap catheter, in conjunction with SuperMap, an algorithm that compiles a large number of non-contact data points from multiple catheter positions within the atria. These studies demonstrate the efficiency, safety and accuracy of this technology.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":"20 2","pages":"45-53"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-02-01Epub Date: 2024-03-08DOI: 10.2217/fca-2023-0146
Nasir Sulemanjee, Vida Vizgirda, Krishna Naik, Chelsea Redman, Lisa Tarasenko, Ira Jacobs
{"title":"A mixed-methods landscape assessment of supportive care for heart failure.","authors":"Nasir Sulemanjee, Vida Vizgirda, Krishna Naik, Chelsea Redman, Lisa Tarasenko, Ira Jacobs","doi":"10.2217/fca-2023-0146","DOIUrl":"10.2217/fca-2023-0146","url":null,"abstract":"<p><p><b>Aim:</b> Understanding factors that shape leading health systems' (LHS) perspectives around heart failure (HF) treatment. <b>Patients & methods:</b> First of its kind study using a cross-sectional, descriptive, mixed-method design (from executives and frontline healthcare providers) with quantitative survey (n = 35) and qualitative interview (n = 12) data from 47 participants (41 different LHS). <b>Results:</b> 97% of LHS had dedicated HF programs, but variations in maturity highlights opportunities for care standardization. Treatment innovations continue, though practitioners may struggle to keep pace amid provider/patient barriers. HF programs strive to co-locate supportive care services to optimize treatment, but access can prove challenging. <b>Conclusion:</b> Opportunities exist, with external partner support, for LHS to become more comprehensive HF care providers, increasing standardization of care across LHS and improved HF treatment.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"55-66"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140061764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-02-01Epub Date: 2024-02-22DOI: 10.2217/fca-2023-0156
James E Ip, Bruce S Stambler, David B Bharucha, Annette Green
{"title":"Plain language summary of the safety and effectiveness of etripamil for atrioventricular-nodal-dependent supraventricular tachycardia: the RAPID study.","authors":"James E Ip, Bruce S Stambler, David B Bharucha, Annette Green","doi":"10.2217/fca-2023-0156","DOIUrl":"10.2217/fca-2023-0156","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a plain language summary of a clinical research study called RAPID. The study looked at the potential for how safe and effective etripamil was at stopping an episode of rapid heartbeats in people with atrioventricularnodal-dependent supraventricular tachycardia (AV-node-dependent SVT). An episode is used to describe the period of time when a person experiences an abnormally very fast heartbeat. This was done by comparing an investigational drug called etripamil with a placebo, each administered via a rapidly acting nasal spray. AV-node-dependent SVT affects the rhythm of the heart, causing it to suddenly beat rapidly. The condition often requires medical treatment to help return the heart to its normal, healthy heartbeat pattern and speed, called 'sinus rhythm'. Researchers are looking at ways of improving the management of supraventricular tachycardias (SVT) by reducing the need for patients to attend an urgent care clinic, emergency ward or hospital for treatment. In the RAPID study, participants used a nasal spray containing either 70 mg etripamil or a placebo solution when they experienced an episode of SVT. The researchers wanted to know how long it took for each participant's rapid heartbeat to return to sinus rhythm after administering the etripamil or placebo nasal spray. Participants in the study were considered successfully treated if their heartbeats returned to sinus rhythm for at least 30 seconds within 30 minutes of using the nasal spray. Although 30 seconds may seem brief, it's medically important because it shows that a person's heartbeat has been temporarily stabilized and returned to normal functioning.</p><p><strong>What were the results?: </strong>Out of 99 people who used etripamil during an SVT episode, 63 participants (64%) experienced a return to sinus rhythm for at least 30 seconds within 30 minutes after using the nasal spray. In contrast, 26 out of 85 participants (31%) who used the placebo nasal spray experienced a return to sinus rhythm for at least 30 seconds within 30 minutes after use. Furthermore, the average time taken for the return to sinus rhythm was 17 minutes for the etripamil group which was 3-times faster than the placebo group at 53 minutes. Also, in the study no serious side effects occurred that were related to etripamil.</p><p><strong>What do the results of the study mean?: </strong>The RAPID study supports the potential that etripamil may be safe and well tolerated by participants as a treatment for episodes of rapid heartbeat in people with AV-node-dependent SVT. The results also showed a significant improvement in symptoms following treatment with etripamil.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"35-44"},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}